Cargando…

Systematic Review of Recurrent Osteosarcoma Systemic Therapy

SIMPLE SUMMARY: Osteosarcoma is the most common primary bone cancer. Its therapeutic approach includes cytotoxic chemotherapy and surgery. However, when recurrence or metastasis occurs the therapeutic options are limited with poor results. Herein we have conducted a systematic review of the systemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gazouli, Ioanna, Kyriazoglou, Anastasios, Kotsantis, Ioannis, Anastasiou, Maria, Pantazopoulos, Anastasios, Prevezanou, Maria, Chatzidakis, Ioannis, Kavourakis, Georgios, Economopoulou, Panagiota, Kontogeorgakos, Vasileios, Papagelopoulos, Panayiotis, Psyrri, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067690/
https://www.ncbi.nlm.nih.gov/pubmed/33917001
http://dx.doi.org/10.3390/cancers13081757
_version_ 1783682861458522112
author Gazouli, Ioanna
Kyriazoglou, Anastasios
Kotsantis, Ioannis
Anastasiou, Maria
Pantazopoulos, Anastasios
Prevezanou, Maria
Chatzidakis, Ioannis
Kavourakis, Georgios
Economopoulou, Panagiota
Kontogeorgakos, Vasileios
Papagelopoulos, Panayiotis
Psyrri, Amanda
author_facet Gazouli, Ioanna
Kyriazoglou, Anastasios
Kotsantis, Ioannis
Anastasiou, Maria
Pantazopoulos, Anastasios
Prevezanou, Maria
Chatzidakis, Ioannis
Kavourakis, Georgios
Economopoulou, Panagiota
Kontogeorgakos, Vasileios
Papagelopoulos, Panayiotis
Psyrri, Amanda
author_sort Gazouli, Ioanna
collection PubMed
description SIMPLE SUMMARY: Osteosarcoma is the most common primary bone cancer. Its therapeutic approach includes cytotoxic chemotherapy and surgery. However, when recurrence or metastasis occurs the therapeutic options are limited with poor results. Herein we have conducted a systematic review of the systemic treatment options in recurrent and/or metastatic osteosarcoma over the last two decades. Our results indicate the paucity of our therapeutic armamentarium for this entity, with the majority of the studied modalities resulting in limited or no benefits. Intense translational research and future clinical studies reveal the unmet need for new treatment options for osteosarcoma patients with metastatic and/or recurrent disease. ABSTRACT: Osteosarcoma is the most frequent primary bone cancer, mainly affecting those of young ages. Although surgery combined with cytotoxic chemotherapy has significantly increased the chances of cure, recurrent and refractory disease still impose a tough therapeutic challenge. We performed a systematic literature review of the available clinical evidence, regarding treatment of recurrent and/or refractory osteosarcoma over the last two decades. Among the 72 eligible studies, there were 56 prospective clinical trials, primarily multicentric, single arm, phase I or II and non-randomized. Evaluated treatment strategies included cytotoxic chemotherapy, tyrosine kinase and mTOR inhibitors and other targeted agents, as well as immunotherapy and combinatorial approaches. Unfortunately, most treatments have failed to induce objective responses, albeit some of them may sustain disease control. No driver mutations have been recognized, to serve as effective treatment targets, and predictive biomarkers of potential treatment effectiveness are lacking. Hopefully, ongoing and future clinical and preclinical research will unlock the underlying biologic mechanisms of recurrent and refractory osteosarcoma, expanding the therapeutic choices available to pre-treated osteosarcoma patients.
format Online
Article
Text
id pubmed-8067690
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80676902021-04-25 Systematic Review of Recurrent Osteosarcoma Systemic Therapy Gazouli, Ioanna Kyriazoglou, Anastasios Kotsantis, Ioannis Anastasiou, Maria Pantazopoulos, Anastasios Prevezanou, Maria Chatzidakis, Ioannis Kavourakis, Georgios Economopoulou, Panagiota Kontogeorgakos, Vasileios Papagelopoulos, Panayiotis Psyrri, Amanda Cancers (Basel) Systematic Review SIMPLE SUMMARY: Osteosarcoma is the most common primary bone cancer. Its therapeutic approach includes cytotoxic chemotherapy and surgery. However, when recurrence or metastasis occurs the therapeutic options are limited with poor results. Herein we have conducted a systematic review of the systemic treatment options in recurrent and/or metastatic osteosarcoma over the last two decades. Our results indicate the paucity of our therapeutic armamentarium for this entity, with the majority of the studied modalities resulting in limited or no benefits. Intense translational research and future clinical studies reveal the unmet need for new treatment options for osteosarcoma patients with metastatic and/or recurrent disease. ABSTRACT: Osteosarcoma is the most frequent primary bone cancer, mainly affecting those of young ages. Although surgery combined with cytotoxic chemotherapy has significantly increased the chances of cure, recurrent and refractory disease still impose a tough therapeutic challenge. We performed a systematic literature review of the available clinical evidence, regarding treatment of recurrent and/or refractory osteosarcoma over the last two decades. Among the 72 eligible studies, there were 56 prospective clinical trials, primarily multicentric, single arm, phase I or II and non-randomized. Evaluated treatment strategies included cytotoxic chemotherapy, tyrosine kinase and mTOR inhibitors and other targeted agents, as well as immunotherapy and combinatorial approaches. Unfortunately, most treatments have failed to induce objective responses, albeit some of them may sustain disease control. No driver mutations have been recognized, to serve as effective treatment targets, and predictive biomarkers of potential treatment effectiveness are lacking. Hopefully, ongoing and future clinical and preclinical research will unlock the underlying biologic mechanisms of recurrent and refractory osteosarcoma, expanding the therapeutic choices available to pre-treated osteosarcoma patients. MDPI 2021-04-07 /pmc/articles/PMC8067690/ /pubmed/33917001 http://dx.doi.org/10.3390/cancers13081757 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Gazouli, Ioanna
Kyriazoglou, Anastasios
Kotsantis, Ioannis
Anastasiou, Maria
Pantazopoulos, Anastasios
Prevezanou, Maria
Chatzidakis, Ioannis
Kavourakis, Georgios
Economopoulou, Panagiota
Kontogeorgakos, Vasileios
Papagelopoulos, Panayiotis
Psyrri, Amanda
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
title Systematic Review of Recurrent Osteosarcoma Systemic Therapy
title_full Systematic Review of Recurrent Osteosarcoma Systemic Therapy
title_fullStr Systematic Review of Recurrent Osteosarcoma Systemic Therapy
title_full_unstemmed Systematic Review of Recurrent Osteosarcoma Systemic Therapy
title_short Systematic Review of Recurrent Osteosarcoma Systemic Therapy
title_sort systematic review of recurrent osteosarcoma systemic therapy
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067690/
https://www.ncbi.nlm.nih.gov/pubmed/33917001
http://dx.doi.org/10.3390/cancers13081757
work_keys_str_mv AT gazouliioanna systematicreviewofrecurrentosteosarcomasystemictherapy
AT kyriazoglouanastasios systematicreviewofrecurrentosteosarcomasystemictherapy
AT kotsantisioannis systematicreviewofrecurrentosteosarcomasystemictherapy
AT anastasioumaria systematicreviewofrecurrentosteosarcomasystemictherapy
AT pantazopoulosanastasios systematicreviewofrecurrentosteosarcomasystemictherapy
AT prevezanoumaria systematicreviewofrecurrentosteosarcomasystemictherapy
AT chatzidakisioannis systematicreviewofrecurrentosteosarcomasystemictherapy
AT kavourakisgeorgios systematicreviewofrecurrentosteosarcomasystemictherapy
AT economopouloupanagiota systematicreviewofrecurrentosteosarcomasystemictherapy
AT kontogeorgakosvasileios systematicreviewofrecurrentosteosarcomasystemictherapy
AT papagelopoulospanayiotis systematicreviewofrecurrentosteosarcomasystemictherapy
AT psyrriamanda systematicreviewofrecurrentosteosarcomasystemictherapy